Does Strattera Hold a Black Box Warning?
Yes, Strattera (atomoxetine) carries an FDA black box warning for increased risk of suicidal ideation in children and adolescents with ADHD. 1
The Black Box Warning Details
The FDA-mandated black box warning specifically addresses suicidal ideation risk in pediatric populations. According to the official FDA drug label, pooled analyses of short-term placebo-controlled trials (6-18 weeks) involving over 2,200 children and adolescents revealed that patients receiving Strattera had a 0.4% risk of suicidal ideation compared to 0% in placebo-treated patients. Importantly, no actual suicides occurred in these trials. 1
Clinical Implications and Monitoring Requirements
Anyone considering Strattera for a child or adolescent must balance this suicidal ideation risk against the clinical need for ADHD treatment. 2 The warning emphasizes that:
- Close monitoring is mandatory when initiating therapy, particularly for suicidality (suicidal thinking and behavior), clinical worsening, or unusual behavioral changes
- Families and caregivers must be counseled about the need for vigilant observation and immediate communication with the prescriber if concerning symptoms emerge
- Co-morbidities with ADHD may independently increase suicide risk, requiring additional clinical consideration 1
Important Context
The 2019 AAP/ADHD clinical practice guidelines acknowledge this black box warning while noting that increased suicidal thoughts occur "less commonly" with atomoxetine. 2 This risk must be weighed against atomoxetine's benefits as a non-stimulant alternative, particularly for patients with:
- Substance abuse risk or history
- Co-morbid anxiety disorders
- Tic disorders
- Preference to avoid controlled substances
The warning applies specifically to the pediatric population (children and adolescents), though Strattera is FDA-approved for both pediatric and adult ADHD patients. The drug label explicitly states that Strattera is NOT approved for major depressive disorder. 1
Practical Monitoring Approach
When prescribing Strattera to children or adolescents:
- Obtain baseline psychiatric history including any prior suicidal ideation or attempts
- Schedule frequent follow-up visits during the first 4-8 weeks of treatment
- Provide families with specific warning signs to monitor (mood changes, withdrawal, agitation, new or worsening depression)
- Establish clear communication protocols for urgent concerns
- Document risk-benefit discussion in the medical record